These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 17361226)

  • 1. Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy.
    Simula MP; Marktel S; Fozza C; Kaeda J; Szydlo RM; Nadal E; Bua M; Rahemtulla A; Kanfer E; Marin D; Olavarria E; Goldman JM; Apperley JF; Dazzi F
    Leukemia; 2007 May; 21(5):943-8. PubMed ID: 17361226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.
    Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; Moreno-Lafont M; García-Latorre E; Ramírez-Sanjuan E; Montiel-Cervantes L; Tripp-Villanueva F; García-León LD; Ayala-Sánchez M; Rosas-Cabral A; Aviña-Zubieta JA; Galindo-Rodríguez G; Vadillo-Buenfil M; Salazar-Exaire D
    Ann Hematol; 2004 May; 83(5):295-301. PubMed ID: 15060749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions.
    Raiola AM; Van Lint MT; Valbonesi M; Lamparelli T; Gualandi F; Occhini D; Bregante S; di Grazia C; Dominietto A; Soracco M; Romagnani C; Vassallo F; Casini M; Bruno B; Frassoni F; Bacigalupo A
    Bone Marrow Transplant; 2003 Apr; 31(8):687-93. PubMed ID: 12692609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.
    Chiorean EG; DeFor TE; Weisdorf DJ; Blazar BR; McGlave PB; Burns LJ; Brown C; Miller JS
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
    Dazzi F; Szydlo RM; Cross NC; Craddock C; Kaeda J; Kanfer E; Cwynarski K; Olavarria E; Yong A; Apperley JF; Goldman JM
    Blood; 2000 Oct; 96(8):2712-6. PubMed ID: 11023502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.
    Savani BN; Montero A; Kurlander R; Childs R; Hensel N; Barrett AJ
    Bone Marrow Transplant; 2005 Dec; 36(11):1009-15. PubMed ID: 16205732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors.
    van Rhee F; Savage D; Blackwell J; Orchard K; Dazzi F; Lin F; Chase A; Bungey J; Cross NC; Apperley J; Szydlo R; Goldman JM
    Bone Marrow Transplant; 1998 May; 21(10):1055-61. PubMed ID: 9632281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation.
    Bacigalupo A; Soracco M; Vassallo F; Abate M; Van Lint MT; Gualandi F; Lamparelli T; Occhini D; Mordini N; Bregante S; Figari O; Benvenuto F; Sessarego M; Fugazza G; Carlier P; Valbonesi M
    Bone Marrow Transplant; 1997 May; 19(9):927-32. PubMed ID: 9156268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia.
    Gilleece MH; Dazzi F
    Leuk Lymphoma; 2003 Jan; 44(1):23-8. PubMed ID: 12691139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late response to donor lymphocyte infusions in patients with chronic myeloid leukemia relapsing after allogeneic stem cell transplantation.
    Gómez M; Urbano-Ispizua A; Cervantes F; Fernández-Avilés F; Rovira M; Carreras E
    Haematologica; 2002 Sep; 87(9):1003-5. PubMed ID: 12217814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
    Román J; Alvarez MA; Torres A
    Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment.
    Dazzi F; Fozza C
    Best Pract Res Clin Haematol; 2007 Jun; 20(2):311-27. PubMed ID: 17448964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand.
    Dazzi F; Szydlo RM; Goldman JM
    Exp Hematol; 1999 Oct; 27(10):1477-86. PubMed ID: 10517488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia].
    Ishikawa I; Miyamura K; Yamada M; Sasaki O; Harigae H; Kameoka J; Meguro K; Sasaki T
    Rinsho Ketsueki; 2005 Dec; 46(12):1288-92. PubMed ID: 16447801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
    Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
    Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
    Huang XJ; Xu LP; Liu KY; Liu DH; Chen H; Liu YR; Chen YH; Han W; Wang Y
    Biol Blood Marrow Transplant; 2011 May; 17(5):649-56. PubMed ID: 20691800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome-positive CML in first chronic phase.
    Schattenberg A; Preijers F; Mensink E; Bär B; Schaap N; Geurts van Kessel A; van der Maazen R; de Witte T
    Bone Marrow Transplant; 1997 Jun; 19(12):1205-12. PubMed ID: 9208114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.